Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials

被引：159

作者：

Agodoa, L. ^{[1
]}

Anderson, C. ^{[1
]}

Asselbergs, F. W. ^{[1
]}

Baigent, C. ^{[1
]}

Black, H. ^{[1
]}

Brenner, B. ^{[1
]}

Brown, M. ^{[1
]}

Bulpitt, C. ^{[1
]}

Byington, R. ^{[1
]}

Chalmers, J. ^{[1
]}

Collins, R. ^{[1
]}

Cutler, J. ^{[1
]}

Dahlof, B. ^{[1
]}

Davis, B. ^{[1
]}

de Zeeuw, D. ^{[1
]}

Dens, J. ^{[1
]}

Estacio, R. ^{[1
]}

Fagard, R. ^{[1
]}

Fox, K. ^{[1
]}

Fukui, T. ^{[1
]}

Hansson, L. ^{[1
]}

Holman, R. ^{[1
]}

Hunsicker, L. ^{[1
]}

Imai, Y. ^{[1
]}

Ishii, M. ^{[1
]}

Kanno, Y. ^{[1
]}

Kostis, J. ^{[1
]}

Kuramoto, K. ^{[1
]}

Lewis, E. ^{[1
]}

Lievre, M. ^{[1
]}

Lindholm, L. H. ^{[1
]}

Liu, L. ^{[1
]}

Lubsen, J. ^{[1
]}

Lueders, S. ^{[1
]}

MacMahon, S. ^{[1
]}

Malacco, E. ^{[1
]}

Mancia, G. ^{[1
]}

Matsuzaki, M. ^{[1
]}

Neal, B. ^{[1
]}

Nissen, S. ^{[1
]}

Ohkubo, T. ^{[1
]}

Ogihara, T. ^{[1
]}

Pepine, C. ^{[1
]}

Pfeffer, M. ^{[1
]}

Pitt, B. ^{[1
]}

Poole-Wilson, P. ^{[1
]}

Poulter, N. ^{[1
]}

Rahman, M. ^{[1
]}

Remme, W. ^{[1
]}

Remuzzi, G. ^{[1
]}

机构：

[1] Univ Sydney, George Inst Global Hlth, Level 13,321 Kent St, Sydney, NSW 2000, Australia

来源：

BMJ-BRITISH MEDICAL JOURNAL | 2013年 / 347卷

基金：

英国医学研究理事会; 澳大利亚研究理事会;

关键词：

CONVERTING-ENZYME-INHIBITORS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; PUBLICATION BIAS; RENAL OUTCOMES; RISK-FACTOR; HYPERTENSION; CORONARY; ATHEROSCLEROSIS; PROGRESSION;

D O I：

10.1136/bmj.f5680

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective To define the cardiovascular effects of lowering blood pressure in people with chronic kidney disease. Design Collaborative prospective meta-analysis of randomised trials. Data sources and eligibility Participating randomised trials of drugs to lower blood pressure compared with placebo or each other or that compare different blood pressure targets, with at least 1000 patient years of follow-up per arm. Main outcome measures Major cardiovascular events (stroke, myocardial infarction, heart failure, or cardiovascular death) in composite and individually and all cause death. Participants 26 trials (152 290 participants), including 30 295 individuals with reduced estimated glomerular filtration rate (eGFR), which was defined as eGFR <60 mL/min/1.73m(2). Data extraction Individual participant data were available for 23 trials, with summary data from another three. Meta-analysis according to baseline kidney function was performed. Pooled hazard ratios per 5 mm Hg lower blood pressure were estimated with a random effects model. Results Compared with placebo, blood pressure lowering regimens reduced the risk of major cardiovascular events by about a sixth per 5 mm Hg reduction in systolic blood pressure in individuals with (hazard ratio 0.83, 95% confidence interval 0.76 to 0.90) and without reduced eGFR (0.83, 0.79 to 0.88), with no evidence for any difference in effect (P=1.00 for homogeneity). The results were similar irrespective of whether blood pressure was reduced by regimens based on angiotensin converting enzyme inhibitors, calcium antagonists, or diuretics/beta blockers. There was no evidence that the effects of different drug classes on major cardiovascular events varied between patients with different eGFR (all P>0.60 for homogeneity). Conclusions Blood pressure lowering is an effective strategy for preventing cardiovascular events among people with moderately reduced eGFR. There is little evidence from these overviews to support the preferential choice of particular drug classes for the prevention of cardiovascular events in chronic kidney disease.

引用

页数：15

共 55 条

[41] Kidney disease as a risk factor for development of cardiovascular disease - A statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention [J].

Sarnak, MJ ;

Levey, AS ;

Schoolwerth, AC ;

Coresh, J ;

Culleton, B ;

Hamm, LL ;

McCullough, PA ;

Kasiske, BL ;

Kelepouris, E ;

Klag, MJ ;

Parfrey, P ;

Pfeffer, M ;

Raij, L ;

Spinosa, DJ ;

Wilson, PW .

HYPERTENSION, 2003, 42 (05) :1050-1065

[42] Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes [J].

Schrier, RW ;

Estacio, RO ;

Esler, A ;

Mehler, P .

KIDNEY INTERNATIONAL, 2002, 61 (03) :1086-1097

[43] Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the prevention of events with ACE inhibition (PEACE) trial [J].

Solomon, Scott D. ;

Rice, Madeline M. ;

Jablonski, Kathleen A. ;

Jose, Powell ;

Domanski, Michael ;

Sabatine, Marc ;

Gersh, Bernard J. ;

Rouleau, Jean ;

Pfeffer, Marc A. ;

Braunwald, Eugene .

CIRCULATION, 2006, 114 (01) :26-31

[44] Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension [J].

Staessen, JA ;

Fagard, R ;

Thijs, L ;

Celis, H ;

Arabidze, GG ;

Birkenhager, WH ;

Bulpitt, CJ ;

deLeeuw, PW ;

Dollery, CT ;

Fletcher, AE ;

Forette, F ;

Leonetti, G ;

Nachev, C ;

OBrien, ET ;

Rosenfeld, J ;

Rodicio, JL ;

Tuomilehto, J ;

Zanchetti, A .

LANCET, 1997, 350 (9080) :757-764

[45]

Stearne MR, 1998, BMJ-BRIT MED J, V317, P703

[46]

Strippoli GF, 2006, COCHRANE DB SYST REV, V18, DOI DOI 10.1002/14651858.CD006257

[47]

Teo KK, 2000, CIRCULATION, V102, P1748

[48] Practical methods for incorporating summary time-to-event data into meta-analysis [J].

Tierney, Jayne F. ;

Stewart, Lesley A. ;

Ghersi, Davina ;

Burdett, Sarah ;

Sydes, Matthew R. .

TRIALS, 2007, 8 (1)

[49]

Turnbull F, 2003, LANCET, V362, P1527

[50] A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly [J].

Wing, LMH ;

Reid, CM ;

Ryan, P ;

Beilin, LJ ;

Brown, MA ;

Jennings, GLR ;

Johnston, CI ;

McNeil, JJ ;

Macdonald, GJ ;

Marley, JE ;

Morgan, TO ;

West, MJ ;

Nelson, M ;

Bruce, A ;

Beckinsale, P ;

Thompson, J ;

McMurchie, M ;

Fraser, G ;

Gleave, D ;

Cope, V ;

DeLooze, F ;

Moore, S ;

Dibben, C ;

Newbury, J ;

Miles, H ;

McDermott, B ;

Willson, K ;

Bear, C ;

West, M ;

Harrap, S ;

Johnston, C ;

Beilin, L ;

Ryan, P ;

Wing, L ;

Reid, C ;

Beilin, L ;

Brown, M ;

Ryan, P ;

Wing, L ;

Reid, C ;

Jennings, G ;

Fletcher, P ;

Feneley, M ;

Dewar, E ;

Wing, L ;

Reid, C ;

McNeil, J ;

Wing, L ;

Marley, J ;

Reid, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :583-592

← 1 2 3 4 5 6 →